Amarin (NASDAQ:AMRN – Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06), Zacks reports. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%.
Amarin Stock Performance
NASDAQ:AMRN opened at $0.43 on Wednesday. The company has a market capitalization of $177.41 million, a price-to-earnings ratio of -4.96 and a beta of 1.82. Amarin has a one year low of $0.40 and a one year high of $1.11. The stock has a 50-day simple moving average of $0.56 and a 200 day simple moving average of $0.55.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Friday, March 7th.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
- Five stocks we like better than Amarin
- What is the Hang Seng index?
- Why Energy Transfer Belongs on Your Watchlist
- What is Forex and How Does it Work?
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Investments to Consider as China’s Market Heats Up
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
